undamentalytics Newsletter
Sign in

Dexcom cash flow statement

In fiscal 2025, Dexcom's operations generated $1.44bn of cash; it spent $364m on capital projects, leaving free cash flow of $1.08bn. It returned $500m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−39−43−30−332244956921233154764436707499901,4411,414
Depreciation and amortisation224778111516294967102156186218252275
Stock-based pay891418255083111106102103119113127151170160154
Capital spending3781081633566667180199389365237359364316
Free cash flow−42−50−38−43−671612656135277533055126311,0771,098
Free cash flow after stock pay−51−59−52−61−30−43−67−110−80−4632157−60178361460918944
Share buybacks———————00100000558689750500—
Shares issued46717541224191010111215202327282825

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BLCO vs DXCMDXCM vs IDXXDXCM vs RMD

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Dexcom's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dexcom.